Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our current portfolio comprises of biotech developing truly disruptive solutions for high unmet medical needs.

Acerta, a multi-billion Euro success story

BioGeneration was co-founder and investor in the most successful biotech startup in Europe: Acerta Pharma. Acerta Pharma has developed Calquence® (acalabrutinib), a drug now approved by the FDA for the treatment of hematologic malignancies (leukemia). Acerta was sold to AstraZeneca for up to US$ 7 billion in 2016.

Shaping new life-science ventures

We gained our experience from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

VectorY raises €31 million in seed financing to develop next-generation gene therapies aimed at muscular and CNS disorders

Jun 15, 2021

Amsterdam, The Netherlands, 15 June 2021 – VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, today announces the...

VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board

Jun 15, 2021

Leiden, The Netherlands, 15 June 2021 - VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Jan Öhrström, as Chief Executive Officer, and of Dr. Alex Gold to the...

Confo Therapeutics Establishes Medical Advisory Board

Jun 10, 2021

Ghent, Belgium – June 10, 2021 - Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of...

CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer

May 4, 2021

Munich, Germany, May 4, 2021 – CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the appointment of Dr. Phil L’Huillier as Chief Executive Officer (CEO), effective May 17, 2021. Dr. Phil L’Huillier brings over two...

News overview

Next events

21-25 June – BioTrinity 2021

Jun 15, 2021

BioTrinity gives an opportunity to share updates on the latest achievments in R&D across all therapy and technology areas. BGV will be attending BioTrinity 2021 which features a packed LIVE agenda of Panels, Industry Insights, Keynotes, BioLaunchPad Presentations...

01 July, 2021 – BGV Partner Daniela Couto at Johnson & Johnson Innovation webinar

May 27, 2021

BGV Partner Daniela Couto will participate in the Johnson & Johnson Innovation webinar "Investor Perspective: How Can Partnering with Pharma Impact Startup Success?" A panel of investors will share their views on collaborating and partnering with pharma companies....

Event overview